Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1, Chem. 2, Chem. 3 or Chem. 4; or a pharmaceutically acceptable salt, amide, or ester thereof.

Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.

Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.

Abstract: The present invention discloses a preparation method for large scale production of human immunoglobulins (IgG) with high yields by an improved all-chromatography process scheme that eliminates ethanol precipitation. The process of extracting immunoglobulins is such that the other therapeutic proteins in plasma are left unaffected and are available for extraction separately from the same plasma sample. The yields obtained are in the range of 7 to 8 grams of IgG per liter of plasma. The high yielding process scheme of the present invention comprises of chromatographic steps and viral inactivation or removal steps to obtain a purified immunoglobulin protein that complies with pharmacopoeial limits and is suitable for therapeutic administration (normal intravenous immunoglobulin—IVIG).

Abstract: The invention relates to a human anti-dengue virus antibody (an anti-DENV antibody) that binds to a DENV envelope protein and is cross-reactive with DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4. The disclosure provides an anti-DENV antibody that cross-reacts with and neutralizes all four DENV serotypes. Also provided is a nucleic acid molecule that encodes such an anti-DENV antibody. Also provided is a method to produce and use such an antibody or nucleic acid molecule encoding such an antibody.

Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:61-121 and 133-141, or the nucleotide sequence set forth in SEQ ID NO:1-60, 124-132, and 142-283, as well as variants and fragments thereof.

Abstract: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.

Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.

Abstract: The invention relates generally to methods for purifying a Fc-fusion protein produced in a eukaryotic expression system. More specifically, the invention provides a robust and scalable downstream purification process suitable for use in manufacturing TNFR:Fc for human administration which comprises an optimized Protein A affinity chromatography step and two ion exchange chromatography steps both of which are operated in the bind-and-elute mode.

Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.

Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.

Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.

Abstract: The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.

Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.

Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.

Abstract: The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.

Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.

Abstract: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.

Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Abstract: A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Abstract: The invention provides an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies and methods of using the same for treating or preventing various diseases in which human IL-23R is involved in the pathogenesis of the diseases.

Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.

Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.

Abstract: Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.

Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).

Abstract: A modified cellulose is provided. The modified cellulose is represented by the chemical formula (1): wherein n is between 60 and 2500, at least one R is selected from one of the group consisting of R1 is C11 to C32 alkyl group or C11 to C32 alkenyl group, R2 is hydrogen, C3 to C29 alkyl group or C3 to C29 alkenyl group, R3 is C3 to C29 alkyl group or C3 to C29 alkenyl group, R4 is C4 to C8 cycloalkyl group or C4 to C8 cycloalkenyl group, n2 is between 15 and 33, n4 is between 20 and 40.

Abstract: A system and method for discharging a transfer slurry from a first polymerization reactor through a transfer line to a second polymerization reactor, the transfer slurry including at least diluent and a first polyethylene. A product slurry is discharged from the second polymerization reactor, the product slurry including at least diluent, the first polyethylene, and a second polyethylene. The velocity, pressure drop, or pressure loss due to friction in the transfer line is determined, and a process variable adjusted in response to the velocity, pressure drop, or pressure loss not satisfying a specified value.

Abstract: The invention relates to multi-stage polymer emulsions suitable for forming pressure sensitive adhesives with high peel and high temperature cohesion.

Abstract: There is provided a catalyst composition for polymerizing a conjugated diene monomer containing a rare earth complex having a specific structure and a specific compound.

Abstract: The invention relates to a catalyst for olefin polymerization represented by the general formula (1): wherein; M is a transition metal; X1 and X2 are independently selected from the group consisting of halide, alkyl group, aryl group, alkyl amine group, or alkyl aryl group, and are directly bond to M, R1 and R2 are independently selected from the group consisting of hydrogen, alkyl group or aryl group; and Cp is a cyclopentadienyl group.

Abstract: Polymers produced by a process comprising contacting one or more olefins with a catalyst system comprising an activator and a Salan catalyst disposed on a support.

Abstract: A system and method for polymerizing olefin in the presence of a chain transfer agent in a first reactor to form a first polyolefin, discharging from the first reactor a transfer slurry having the first polyolefin and the chain transfer agent, and processing the transfer slurry in a separator to remove chain transfer agent and to provide a fluff slurry having the first polyolefin and a lower content of chain transfer agent than in the transfer slurry. The system and method provide for feeding the fluff slurry to a second reactor, polymerizing olefin in the second reactor to form a second polyolefin, and discharging from the second reactor a slurry having the second polyolefin.

Abstract: The present invention relates to a supported hybrid catalyst and a method for preparing an olefin based polymer using the same. The supported hybrid catalyst according to the present invention can be used in the preparation of an olefin-based polymer, and the olefin-based polymer prepared using the supported hybrid catalyst has excellent processability and mechanical properties and thus can be effectively used for the application of films or the like.

Abstract: To provide a method for producing a compound that enhances dispersibility of a pigment of respective colors in a water-insoluble solvent, as well as a pigment dispersant, and a pigment composition, a pigment dispersion and a toner having a good tinting power. A method for producing a compound, including the following: (i): subjecting a polymerizable monomer forming a monomer unit represented by formula (1) to radical polymerization in the presence of a radical polymerization initiator and an iodine molecule to provide a polymer; and (ii): binding a colorant to a terminal of a main chain of the polymer: wherein R1 represents a hydrogen atom and an alkyl group, and R2 represents a phenyl group, a carboxyl group, an alkoxycarbonyl group or a carboxamide group.

Abstract: The present disclosure is directed to a process for producing olefin-based polymer in a gas phase polymerization reactor. The process includes forming a wet zone in the gas phase polymerization reactor. The wet zone is formed by maintaining a temperature less than or equal to the fluidizing medium dew point temperature+2° C. in a region of the reactor. The region is defined as the region extending from the distributor plate to 2.5 meters above the distributor plate. Injection of a high activity catalyst composition in the wet zone produces olefin-based having a settled bulk density greater than 23.5 lb/ft3.

Abstract: The present invention aims to reduce excess scattering in light emitting arrangements. A composition comprising a transparent matrix comprising an anionic organic moiety, and metal cations dispersed in the matrix is disclosed. The anionic organic moiety and the metal cations form an organometallic complex, and wherein the metal cations are capable of forming transparent nano-crystals upon contact with an agent comprising at least one element selected from the group consisting of sulfur and selenium. Also an optical composition comprising a transparent matrix comprising an organic moiety residue, and unmodified nanocrystals is disclosed. Further, a method of preparing an optical composition comprising the steps of: providing a transparent matrix comprising an anionic organic moiety; dispersing metal cations into the matrix; and contacting the organometallic complex with an agent in order to in situ convert at least part of the metal cations into transparent nanocrystals.

Abstract: The present invention is directed to polyisocyanates and polyurethanes derived therefrom. In various embodiments, the present invention provides polyisocyanates, methods of making the polyisocyanates from fused bicyclic alcohols, polyurethanes, and methods of making the polyurethanes from the polyisocyanates.

Abstract: A magnetic particle-polymer hybrid material can include: a substance having a structure of Formula 1 or derivative or salt thereof: Z(L-FP)m (Formula 1), wherein: Z is a magnetic particle smaller than 1 mm; m is a positive integer and defines the number of (L-FP) coupled to the Z; L is a linker linked to the magnetic particle; FP is a functionalized polymer having: a first structure derived from a first norbornene compound linked to the magnetic particle through the L; and one or more monomeric units each including a second structure derived from a second norbornene compound, where one of the monomeric units is linked to the first structure through a saturated or unsaturated alkyl, each monomeric unit includes a functional group capable of binding with another substance.

Abstract: Procatalyst comprising an inorganic support, a chlorine compound carried on said support, a magnesium compound carried on said support, a titanium compound carried on said support, and a compound comprising two oxygen containing rings, wherein said two rings are linked via a bridge selected from the group consisting of carbon bridge, silicon bridge, ethane-1.2-diyl bridge, ethene-1,2-diyl bridge, alkylaminomethyl bridge and imine bridge.

Abstract: This invention describes a process for metathesis of olefins from feedstocks obtained from the Fischer-Tropsch process, using as catalyst a ruthenium alkylidene complex comprising a saturated or unsaturated, dissymmetrical N-heterocyclic carbene (NHC) ligand.

Abstract: A method for providing a polymer having terminal functionality involves reacting a terminally active polymer with an ?,?-ethylenically unsaturated compound that includes a group 2-13 element so as to provide a functionalized polymer. The resulting polymer exhibits enhanced interactivity with particulate fillers and can be used in the manufacture of vulcanizates.

Abstract: Described herein is a method of making a fluoropolymer and fluoropolymers thereof, wherein the method comprises: (a) providing an aqueous solution comprising a water soluble polyiodide salt of Formula (I): M+y[I—I—(I)n]y? wherein M is a cation group having a valence y, y is an integer of at least 1 and n is an integer of at least 1; and (b) initiating polymerization of a monomer in the aqueous solution, wherein the monomer is a fluorinated monomer.

Abstract: The invention relates to a copolymer whose overall structure as such and/or an optionally present segment A having at least 10 bivalent structural units in the overall structure contains surface-active bivalent structural units present in the form of long hydrocarbon chains among other forms. The copolymer is effective as a universal surface-active additive, especially also in conjunction with nonpolar media.